• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

David E. Fisher, MD, PhD


  • Liu S, Wang J, Su Y, Guerrero C, Zeng Y, Mitra D, Brooks PJ, Fisher DE, Song H, Wang Y.Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA.Nucleic Acids Res. 2013 May 8.
  • Alves CP, Moraes MH, Sousa JF, Pontes CL, Ramão A, Yokoyama S, Trindade DM, Fisher DE, Espreafico EM.Myosin-Va Contributes to Manifestation of Malignant-Related Properties in Melanoma Cells.J Invest Dermatol. 2013 May 7.
  • Morgan AM, Lo J, Fisher DE.How does pheomelanin synthesis contribute to melanomagenesis?: Two distinct mechanisms could explain the carcinogenicity of pheomelanin synthesis.Bioessays. 2013 May 7.
  • Haq R, Fisher DE.Targeting melanoma by small molecules: Challenges ahead.Pigment Cell Melanoma Res. 2013 Apr 24.
  • Korman JB, Fisher DE.Developing melanoma therapeutics: overview and update.Wiley Interdisciplinary Reviews. Systems Biology And Medicine. 2013 May;5(3):257-71.
  • Balk SJ, Fisher DE, Geller AC.Teens and indoor tanning: a cancer prevention opportunity for pediatricians.Pediatrics. 2013 Apr;131(4):772-85.
  • Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR.Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF.Cancer Cell. 2013 Mar 18;23(3):302-15.
  • Fink EC, Fisher DE.BRAF and MC1R in melanoma: different in head and neck tumors?.J Invest Dermatol. 2013 Apr;133(4):878-80.
  • Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE.BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4321-6.
  • Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA.BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.Clin Cancer Res. 2013 Mar 1;19(5):1225-31.
  • Balk SJ, Fisher DE, Geller AC.Stronger laws are needed to protect teens from indoor tanning.Pediatrics. 2013 Mar;131(3):586-8.
  • Shoag J, Haq R, Zhang M, Liu L, Rowe GC, Jiang A, Koulisis N, Farrel C, Amos CI, Wei Q, Lee JE, Zhang J, Kupper TS, Qureshi AA, Cui R, Han J, Fisher DE, Arany Z.PGC-1 coactivators regulate MITF and the tanning response.Mol Cell. 2013 Jan 10;49(1):145-57.
  • Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE.An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.Nature. 2012 Nov 15;491(7424):449-53.
  • Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G, Fisher DE, Ramaswamy S, Wagner SN.Dual Suppression of the Cyclin-Dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma.Journal of the National Cancer Institute. 2012 Nov 7;104(21):1673-9.
  • Geller AC, Balk SJ, Fisher DE.Stemming the tanning bed epidemic: time for action.J Natl Compr Canc Netw. 2012 Oct 1;10(10):1311-4.
  • Anghel SI, Correa-Rochal R, Budinska E, Boliganl KF, Abraham S, Colombetti S, Fontao L, Mariotti A, Rimoldi D, Ghanem GE, Fisher DE, Lévy F, Delorenzi M, Piguet V.Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF.Pigment Cell Melanoma Res. 2012 Jul;25(4):482-7.
  • Tsao H, Chin L, Garraway LA, Fisher DE.Melanoma: from mutations to medicine.Genes Dev. 2012 Jun 1;26(11):1131-55.
  • Flaherty KT, Hodi FS, Fisher DE.From genes to drugs: targeted strategies for melanoma.Nat Rev Cancer. 2012 May;12(5):349-61. Review.
  • Amrein PC, Attar EC, Takvorian RW, Hochberg EP, Ballen KK, Leahy KM, Fisher DE, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg DS, Brown JR.Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.Clin Cancer Res. 2011 Mar 14.
  • Levy C, Fisher DE.Dual roles of lineage restricted transcription factors: The case of MITF in melanocytes.Transcr. 2011 1;2(1):19-22.
  • Mitra D, Robinson KC, Fisher DE.Melanoma and viagra: an unexpected connection.Pigment Cell Melanoma Res. 2011 Feb;24(1):16-8.
  • D'Orazio J, Fisher DE.Central role for cAMP signaling in pigmentation and UV resistance.Cell Cycle. 2011 Jan 1;10(1):8-9.
  • Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, Chen PH, Li S, Fletcher AL, Yokoyama S, Scott KL, Garraway LA, Song JS, Granter SR, Turley SJ, Fisher DE, Novina CD.Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma.Mol Cell. 2010 Dec 10;40(5):841-849.
  • Ko JM, Fisher DE.A new era: melanoma genetics and therapeutics.J Pathol. 2011 Jan;223(2):241-50. Review.
  • Liu JJ, Fisher DE.Lighting a path to pigmentation: mechanisms of MITF induction by UV.Pigment Cell Melanoma Res. 2010 Dec;23(6):741-5.
  • Khaled M, Levy C, Fisher DE.Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit.Genes Dev. 2010 Oct 15;24(20):2276-81.
  • Weinstock MA, Fisher DE.Indoor ultraviolet tanning: what the data do and do not show regarding risk of melanoma and keratinocyte malignancies.J Natl Compr Canc Netw. 2010 Sep;8(8):867-73.
  • Fisher DE, James WD.Indoor tanning--science, behavior, and policy.N Engl J Med. 2010 Sep 2;363(10):901-3.
  • Garibyan L, Fisher DE.How sunlight causes melanoma.Curr Oncol Rep. 2010 Sep;12(5):319-26.
  • Park JM, Fisher DE.Testimony from the bedside: from Coley's toxins to targeted immunotherapy.Cancer Cell. 2010 Jul 13;18(1):9-10.
  • Weinberg R, Fisher DE, Rich J.Dynamic and transient cancer stem cells nurture melanoma.Nat Med. 2010 Jul;16(7):758.
  • Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA.Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.Cancer Res. 2010 Jul 1;70(13):5213-9.
  • Levy C, Khaled M, Robinson KC, Veguilla RA, Chen PH, Yokoyama S, Makino E, Lu J, Larue L, Beermann F, Chin L, Bosenberg M, Song JS, Fisher DE.Lineage-specific transcriptional regulation of DICER by MITF in melanocytes.Cell. 2010 Jun 11;141(6):994-1005.
  • Stewart RA, Sanda T, Widlund HR, Zhu S, Swanson KD, Hurley AD, Bentires-Alj M, Fisher DE, Kontaridis MI, Look AT, Neel BG.Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.Dev Cell. 2010 May 18;18(5):750-62.
  • Gordon PM, Fisher DE.Role for the pro-apoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT dependent gastrointestinal stromal tumor cell line.J Biol Chem. 2010 May 7;285(19):14109-14.
  • Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nusbaum C, Garraway LA.Integrative analysis of the melanoma transcriptome.Genome Res. 2010 Apr;20(4):413-27.
  • Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA.An oncogenic role for ETV1 in melanoma.Cancer Res. 2010 Mar 1;70(5):2075-84.
  • Nishimura EK, Suzuki M, Igras V, Du J, Lonning S, Miyachi Y, Roes J, Beermann F, Fisher DE.Key roles for transforming growth factor beta in melanocyte stem cell maintenance.Cell Stem Cell. 2010 Feb 5;6(2):130-40.
  • Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE.Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.Cancer Res. 2010 Jan 15;70(2):639-45.
  • Yokoyama S, Salma N, Fisher DE.MITF pathway mutations in melanoma.Pigment Cell Melanoma Res. 2009 Aug;22(4):376-7.
  • Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L.GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.Nature. 2009 Jun 25;459(7250):1085-90.
  • Schulman JM, Fisher DE.Indoor ultraviolet tanning and skin cancer: health risks and opportunities.Curr Opin Oncol. 2009 Mar;21(2):144-9. Review.
  • Zhao X,Graves C,Ames SJ,Fisher DE,Spanjaard RA.Mechanism of Regulation and Suppression of Melanoma Invasiveness by Novel Retinoic Acid Receptor-{gamma} Target Gene Carbohydrate Sulfotransferase 10.Cancer Res. 2009 Jun 15;69(12):5218-25.
  • Mitra D,Fisher DE.Transcriptional regulation in melanoma.Hematol Oncol Clin North Am. 2009 Jun;23(3):447-65, viii. Review.
  • Fisher DE.Advances in melanoma. Preface.Hematol Oncol Clin North Am. 2009 Jun;23(3):xiii-xiv.
  • Robinson KC,Fisher DE.Specification and loss of melanocyte stem cells.Semin Cell Dev Biol. 2009 Feb;20(1):111-6. Review.
  • Ozsolak F,Poling LL,Wang Z,Liu H,Liu XS,Roeder RG,Zhang X,Song JS,Fisher DE.Chromatin structure analyses identify miRNA promoters.Genes Dev. 2008 Nov 15;22(22):3172-83.
  • Jiang X,Zhou J,Yuen NK,Corless CL,Heinrich MC,Fletcher JA,Demetri GD,Widlund HR,Fisher DE,Hodi FS.Imatinib targeting of KIT-mutant oncoprotein in melanoma.Clin Cancer Res. 2008 Dec 1;14(23):7726-32.
  • Osawa M,Fisher DE.Notch and melanocytes: diverse outcomes from a single signal.J Invest Dermatol. 2008 Nov;128(11):2571-4.
  • Hodi FS,Fisher DE.Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma.Nat Clin Pract Oncol. 2008 Dec;5(12):696-7.
  • Tran TT,Schulman J,Fisher DE.UV and pigmentation: molecular mechanisms and social controversies.Pigment Cell Melanoma Res. 2008 Oct;21(5):509-16. Review.
  • Yokoyama S,Feige E,Poling LL,Levy C,Widlund HR,Khaled M,Kung AL,Fisher DE.Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.Pigment Cell Melanoma Res. 2008 Aug;21(4):457-63.
  • Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A.Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept.Leuk Lymphoma. 2008 May;49(5):902-9.
  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE.Major response to imatinib mesylate in KIT-mutated melanoma.J Clin Oncol. 2008 Apr 20;26(12):2046-51.
  • Fisher DE, Medrano EE, McMahon M, Soengas MS, Schuchter L, Wolchok JD, Merlino G.Meeting Report: Fourth International Congress of the Society for Melanoma Research.Pigment Cell Melanoma Res. 2008 Feb;21(1):15-26.
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP.Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25.
  • Sato-Jin K, Nishimura EK, Akasaka E, Huber W, Nakano H, Miller A, Du J, Wu M, Hanada K, Sawamura D, Fisher DE, Imokawa G.Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders.FASEB J. 2008 Apr;22(4):1155-68.
  • Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK.The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.Arthritis Rheum. 2007 Oct 15;57(7):1151-7.
  • Widlund HR, Fisher DE.Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis.Pigment Cell Res. 2007 Oct;20(5):339-40.
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS.Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.Biol Blood Marrow Transplant. 2007 Sep;13(9):1057-65.
  • Kawakami A, Sakane F, Imai S, Yasuda S, Kai M, Kanoh H, Jin HY, Hirosaki K, Yamashita T, Fisher DE, Jimbow K.Rab7 regulates maturation of melanosomal matrix protein gp100/Pmel17/Silv.J Invest Dermatol. 2008 Jan;128(1):143-50.
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR.Phase I trial of parathyroid hormone to facilitate stem cell mobilization.Biol Blood Marrow Transplant. 2007 Jul;13(7):838-43.
  • Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR, Fisher DE.Central role of p53 in the suntan response and pathologic hyperpigmentation.Cell. 2007 Mar 9;128(5):853-64.
  • Lin JY, Fisher DE.Melanocyte biology and skin pigmentation.Nature. 2007 Feb 22;445(7130):843-50. Review.
  • Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, La M, Fisher DE, Ladanyi M.TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.Cancer Res. 2007 Feb 1;67(3):919-29.
  • Ozsolak F, Song JS, Liu XS, Fisher DE.High-throughput mapping of the chromatin structure of human promoters.Nat Biotechnol. 2007 Feb;25(2):244-8.
  • Chang EJ, Kim HJ, Ha J, Kim HJ, Ryu J, Park KH, Kim UH, Lee ZH, Kim HM, Fisher DE, Kim HH.Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4.J Cell Sci. 2007 Jan 1;120(Pt 1):166-76.
  • D'Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter SR, Nishimura EK, Ito S, Fisher DE.Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning.Nature. 2006 Sep 21;443(7109):340-4.
  • Chin L, Garraway LA, Fisher DE.Malignant melanoma: genetics and therapeutics in the genomic era.Genes Dev. 2006 Aug 15;20(16):2149-82. Review.
  • Levy C, Khaled M, Fisher DE.MITF: master regulator of melanocyte development and melanoma oncogene.Trends Mol Med. 2006 Sep;12(9):406-14. Review.
  • Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR."Lineage Addiction" in Human Cancer: Lessons from Integrated Genomics.Cold Spring Harb Symp Quant Biol. 2005;70:25-34.
  • Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT, Lessnick SL, Linehan WM, Kung AL, Fisher DE.Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.Cancer Cell. 2006 Jun;9(6):473-84.
  • McGill GG, Haq R, Nishimura EK, Fisher DE.c-Met expression is regulated by Mitf in the melanocyte lineage.J Biol Chem. 2006 Apr 14;281(15):10365-73.
  • Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Jnne PA.Inhibition of the met receptor in mesothelioma.Clin Cancer Res. 2005 Nov 15;11(22):8122-30.
  • Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR."Lineage Addiction" in Human Cancer: Lessons from Integrated Genomics.Cold Spring Harb Symp Quant Biol. 2005;70:1-10.
  • Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, Kim N.Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis.J Biol Chem. 2005 Oct 21;280(42):35209-16.
  • Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.Nature. 2005 Jul 7;436(7047):117-22.
  • Hershey CL, Fisher DE.Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform.Gene. 2005 Feb 28;347(1):73-82.
  • Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI.BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.Curr Biol. 2005 Feb 8;15(3):249-54.
  • Argani P, La M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, Fisher DE, Ladanyi M.Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.Am J Surg Pathol. 2005 Feb;29(2):230-40.
  • Mertens F, Fletcher CD, Antonescu CR, Coindre JM, Colecchia M, Domanski HA, Downs-Kelly E, Fisher C, Goldblum JR, Guillou L, Reid R, Rosai J, Sciot R, Mandahl N, Panagopoulos I.Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene.Lab Invest. 2005 Mar;85(3):408-15.
  • Nishimura EK, Granter SR, Fisher DE.Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche.Science. 2005 Feb 4;307(5710):720-4.
  • Miller AJ, Levy C, Davis IJ, Razin E, Fisher DE.Sumoylation of MITF and its related family members TFE3 and TFEB.J Biol Chem. 2005 Jan 7;280(1):146-55.
  • Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE.Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma.Cancer Res. 2004 Jan 15;64(2):509-16.
  • Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE.MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.Am J Pathol. 2003 Jul;163(1):333-43.
  • Davis IJ, Hsi BL, Arroyo JD, Vargas SO, Yeh YA, Motyckova G, Valencia P, Perez-Atayde AR, Argani P, Ladanyi M, Fletcher JA, Fisher DE.Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation.Proc Natl Acad Sci U S A. 2003 May 13;100(10):6051-6.
  • Selzer E, Thallinger C, Hoeller C, Oberkleiner P, Wacheck V, Pehamberger H, Jansen B.Betulinic acid-induced Mcl-1 expression in human melanoma--mode of action and functional significance.Mol Med. 2002 Dec;8(12):877-84.
  • Ding HF, Fisher DE.Induction of apoptosis in cancer: new therapeutic opportunities.Ann Med. 2002;34(6):451-69.
  • Sheffield MV, Yee H, Dorvault CC, Weilbaecher KN, Eltoum IA, Siegal GP, Fisher DE, Chhieng DC.Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.Am J Clin Pathol. 2002 Dec;118(6):930-6.
  • Baksh S, Widlund HR, Frazer-Abel AA, Du J, Fosmire S, Fisher DE, DeCaprio JA, Modiano JF, Burakoff SJ.NFATc2-mediated repression of cyclin-dependent kinase 4 expression.Mol Cell. 2002 Nov;10(5):1071-81.
  • Widlund HR, Horstmann MA, Price ER, Cui J, Lessnick SL, Wu M, He X, Fisher DE.Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor.J Cell Biol. 2002 Sep 16;158(6):1079-87.
  • Motyckova G, Fisher DE.Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.Curr Mol Med. 2002 Aug;2(5):407-21.
  • McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, Jordan SA, Jackson IJ, Korsmeyer SJ, Golub TR, Fisher DE.Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.Cell. 2002 Jun 14;109(6):707-18.
  • Selzer E, Wacheck V, Lucas T, Heere-Ress E, Wu M, Weilbaecher KN, Schlegel W, Valent P, Wrba F, Pehamberger H, Fisher D, Jansen B.The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma.Cancer Res. 2002 Apr 1;62(7):2098-103.
  • Granter SR, Weilbaecher KN, Quigley C, Fisher DE.Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma.Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):47-51.
  • Fisher DE.Pathways of apoptosis and the modulation of cell death in cancer.Hematol Oncol Clin North Am. 2001 Oct;15(5):931-56, ix.
  • Weilbaecher KN, Motyckova G, Huber WE, Takemoto CM, Hemesath TJ, Xu Y, Hershey CL, Dowland NR, Wells AG, Fisher DE.Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice.Mol Cell. 2001 Oct;8(4):749-58.
  • Dorvault CC, Weilbaecher KN, Yee H, Fisher DE, Chiriboga LA, Xu Y, Chhieng DC.Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.Cancer. 2001 Oct 25;93(5):337-43.
  • Fisher DE.Turning p53 on or off: either way may treat cancer.Drug Resist Updat. 2000 Apr;3(2):77-79.
  • Bates RC, Edwards NS, Burns GF, Fisher DE.A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.Cancer Res. 2001 Jul 1;61(13):5275-83.
  • Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE.Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.Am J Dermatopathol. 2001 Jun;23(3):185-9.
  • Fisher DE.The p53 tumor suppressor: critical regulator of life & death in cancer.Apoptosis. 2001 Feb-Apr;6(1-2):7-15.
  • Ding HF, Fisher DE.p53, caspase 8, and regulation of apoptosis after ionizing radiation.J Pediatr Hematol Oncol. 2001 Mar-Apr;23(3):185-8.
  • Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE.Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: further evidence for melanocytic differentiation.Mod Pathol. 2001 Jan;14(1):6-9.
  • Pruschy M, Rocha S, Zaugg K, Tenzer A, Hess C, Fisher DE, Glanzmann C, Bodis S.Key targets for the execution of radiation-induced tumor cell apoptosis: the role of p53 and caspases.Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):561-7.
  • King R, Googe PB, Weilbaecher KN, Mihm MC, Fisher DE.Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.Am J Surg Pathol. 2001 Jan;25(1):51-7.
  • Ding HF, Lin YL, McGill G, Juo P, Zhu H, Blenis J, Yuan J, Fisher DE.Essential role for caspase-8 in transcription-independent apoptosis triggered by p53.J Biol Chem. 2000 Dec 8;275(49):38905-11.
  • Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J.Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.Cancer Biother Radiopharm. 2000 Feb;15(1):15-29.
  • Sellers WR, Fisher DE.Apoptosis and cancer drug targeting.J Clin Invest. 1999 Dec;104(12):1655-61.
  • King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, Fisher DE.Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.Am J Pathol. 1999 Sep;155(3):731-8.
  • Arbiser JL, Raab G, Rohan RM, Paul S, Hirschi K, Flynn E, Price ER, Fisher DE, Cohen C, Klagsbrun M.Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity.Am J Pathol. 1999 Sep;155(3):723-9.
  • Swingler S, Mann A, Jacqu J, Brichacek B, Sasseville VG, Williams K, Lackner AA, Janoff EN, Wang R, Fisher D, Stevenson M.HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages.Nat Med. 1999 Sep;5(9):997-103.
  • McGill G, Fisher DE.p53 and cancer therapy: a double-edged sword.J Clin Invest. 1999 Aug;104(3):223-5.
  • Hardenbergh PH, Hahnfeldt P, Hlatky L, Takemoto C, Shimamura A, McGill G, Fung CY, Bodis S, Fisher DE.Distinct mathematical behavior of apoptotic versus non-apoptotic tumor cell death.Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):601-5.
  • Price ER, Horstmann MA, Wells AG, Weilbaecher KN, Takemoto CM, Landis MW, Fisher DE.alpha-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome.J Biol Chem. 1998 Dec 4;273(49):33042-7.
  • Ding HF, McGill G, Rowan S, Schmaltz C, Shimamura A, Fisher DE.Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system.J Biol Chem. 1998 Oct 23;273(43):28378-83.
  • Schmaltz C, Hardenbergh PH, Wells A, Fisher DE.Regulation of proliferation-survival decisions during tumor cell hypoxia.Mol Cell Biol. 1998 May;18(5):2845-54.
  • Weilbaecher KN, Hershey CL, Takemoto CM, Horstmann MA, Hemesath TJ, Tashjian AH, Fisher DE.Age-resolving osteopetrosis: a rat model implicating microphthalmia and the related transcription factor TFE3.J Exp Med. 1998 Mar 2;187(5):775-85.
  • Westphal CH, Rowan S, Schmaltz C, Elson A, Fisher DE, Leder P.atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity.Nat Genet. 1997 Aug;16(4):397-401.
  • Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J.CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.Blood. 1997 Apr 15;89(8):3039-47.
  • McCormick RJ, Badalian T, Fisher DE.The leucine zipper may induce electrophoretic mobility anomalies without DNA bending.Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14434-9.
  • Fung CY, Fisher DE.p53: from molecular mechanisms to prognosis in cancer.J Clin Oncol. 1995 Apr;13(4):808-11.
  • Parvin JD, McCormick RJ, Sharp PA, Fisher DE.Pre-bending of a promoter sequence enhances affinity for the TATA-binding factor.Nature. 1995 Feb 23;373(6516):724-7.
  • Hemesath TJ, Steingrmsson E, McGill G, Hansen MJ, Vaught J, Hodgkinson CA, Arnheiter H, Copeland NG, Jenkins NA, Fisher DE.microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family.Genes Dev. 1994 Nov 15;8(22):2770-80.
  • Fisher DE, Parent LA, Sharp PA.High affinity DNA-binding Myc analogs: recognition by an alpha helix.Cell. 1993 Feb 12;72(3):467-76.
  • Fisher DE, Parent LA, Sharp PA.Myc/Max and other helix-loop-helix/leucine zipper proteins bend DNA toward the minor groove.Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11779-83.
  • Reeves WH, Fisher DE, Wisniewolski R, Gottlieb AB, Chiorazzi N.Psoriasis and Raynaud's phenomenon associated with autoantibodies to U1 and U2 small nuclear ribonucleoproteins.N Engl J Med. 1986 Jul 10;315(2):105-11.
  • Fisher DE, Conner GE, Reeves WH, Wisniewolski R, Blobel G.Small nuclear ribonucleoprotein particle assembly in vivo: demonstration of a 6S RNA-free core precursor and posttranslational modification.Cell. 1985 Oct;42(3):751-8.
  • Fisher DE, Reeves WH, Conner GE, Blobel G, Kunkel HG.Pulse labeling of small nuclear ribonucleoproteins in vivo reveals distinct patterns of antigen recognition by human autoimmune antibodies.Proc Natl Acad Sci U S A. 1984 May;81(10):3185-9.